CAS NO: | 701213-36-7 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
2mg | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Temsavir (BMS-626529) is a novel attachment inhibitor that targetsHIV-1gp120 and prevents its binding toCD4+T cells. | ||||||||||||||||
IC50& Target | HIV-1[1] | ||||||||||||||||
体外研究 (In Vitro) | Temsavir has half-maximal effective concentration (EC50) values of<10 nm against the vast majority of viral isolates. temsavir exhibits an average ec50against LAI virus of 0.7±0.4 nM. Temsavir exhibits an EC50of 0.01 nM against the most susceptible virus and an EC50of >2,000 nM against the least susceptible virus. The cytotoxicity profile of Temsavir is examined in several cell types from different human tissues. CC50values of >200 μM are observed in MT-2 (T lymphocytes), HEK293 (kidney), HEp-2 (larynx), HepG2 (liver), HeLa (cervix), HCT116 (colorectal), MCF-7 (breast), SK-N-MC (neuroepithelium), HOS (bone), H292 (lung), and MDBK (bovine kidney) cells measured after 3 or 6 days in culture. CC50values of 105 and 192 μM are obtained in the T-cell line PM1 and in PBMCs, respectively, following 6 days in culture. These results show that Temsavir exhibits low cytotoxicity in cell culture[1]. Temsavir exhibits a broad spectrum of antiviral activity against a panel of clinical isolates, with a 50% inhibitory concentration (IC50) ranging from subnanomolar levels to >0.1 μM[2]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 473.48 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C24H23N7O4 | ||||||||||||||||
CAS 号 | 701213-36-7 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 16.67 mg/mL(35.21 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|